FIG. 1



Tumor Volume (Mean + SEM, mm 3)
2000
1500
1000
500
0
1
6
11
16
21
26
31
36
41
Treatment Day
Vehicle
3 mpk, 32% TGI, p = 0.06
10 mpk; 44% TGI, p = 0.02
30 mpk; 55% TGI, p = 0.007
60 mpk; 84% TGI, p = 0.001
1 PR, 3 SD
100 mpk; 95% TGI, p<0.001
1 CR, 1 PR, 4 MR, 1 SD
TI=10

FIG. 2



% of Control Hemoglobin
100
90
80
70
60
50
40
30
20
10
0
Matrigel
FGF
100
30
10
3
Study #1
300
200
100
30
10
3
Study #2
mg/kg/day

FIG. 3



Mean Tumor Volume + SEM
2500
2000
1500
1000
500
0
0
5
10
15
20
25
Days Post Staging
Vehicle
100 mpk qd, days 1-11
100 mpk q 4 days
100 mpk q 3 days
100 mpk q 2 days

FIG. 4



Vehicle
10 mpk, 20% TGI, p > 0.05
30 mpk, 45% TGI, p = 0.002
60 mpk, 45% TGI, p = 0.002
100 mpk, 72% TGI, p < 0.001
150 mpk, 82% TGI, p < 0.001
TI=5
Mean Tumor Volume ± SEM (mm³)
Treatment Day
0
500
1000
1500
2000
2500
5
10
15
20

FIG. 5



Vehicle
10 mpk Ex. 166
10 mpk CPT-11
Ex. 166 + CPT-11
p<0.005 vs. CPT-11
3 CR
Mean Tumor Vol (mm³ ± SE)
2000
1500
1000
500
0
0
5
10
15
20
25
30
Days Post Staging
Cyclic dose scheduling
CPT-11 dose cycles
10mpk Ex. 166 qd

FIG. 6



10 mpk CPT-11
Cyclic 50 mpk Ex. 166
50 mpk cyclic Ex. 166 + CPT-11
p =<0.001 vs CPT-11
3 CR, PR
Mean Tumor Volume (mm ³±SE)
1000
800
600
400
200
0
0
5
10
15
20
25
30
Days Post Staging
CPT-11 Dosing
50 mpk Ex. 166 dosing between CPT-11 cycles
Cyclic dose scheduling

FIG. 7



Mean Tumor Volume±SEM (mm3)
1200
1000
800
600
400
200
0
1
6
11
16
21
26
31
Days Post Staging
Vehicle
1.5 mpk trastuzumab 2x wk
15 mpk trastuzumab 2x wk (1 PR, 1 CR)
30 mpk Ex. 166 qd (1 PR)
30 mpk Ex. 166 qd + 1.5 mpk trastuzumab 2x wk (1 PR)
30 mpk Ex. 166 qd + 15 mpk trastuzumab 2x wk (4 PR)

FIG. 8



Mean Tumor Volume Mean + SE (mm3)
1000
900
800
700
600
500
400
300
200
100
0
0
4
8
12
16
20
Days Post Staging
Vehicle (1 PR)
25 mpk Ex. 166 (1 PR)
50 mpk Ex. 166 (1 PR)
50 mpk ZD1839 (2 PR)
25 mpk Ex. 166 + ZD1839 (7 PR)
50 mpk Ex. 166 + ZD1839 (8 PR)

FIG. 9A



Number of cells per Field
300
250
200
150
100
50
0
Example 166 (μM)
- - 0.05 0.2 0.5 1.0 2.0
VEGF 50 ng/mL
- - + + + + +

FIG. 9B



Number of Tubes per Field
30.0
25.0
20.0
15.0
10.0
5.0
0.0
Example 166 (μM)
- - 0.1 0.2 0.5 1.0
VEGF 50 ng/mL
- - + + + +

FIG. 10



Number of Cells per Field
250
200
150
100
50
0
-
0.1
0.5
1.0
Example 166 (μM)

FIG. 11



vehicle
10 mpk Ex. 166
>92% TGI, (1CR, 6 PR)
30 mpk Ex. 166
>94% TGI (1 CR; 7 PR)
70 mpk Ex. 166
>96% TGI (1CR; 9PR)
Mean Tumor Volume (mm3 + SE)
400
350
300
250
200
150
100
50
0
0
10
20
30
40
50
60
70
80
Days Post Staging
Stop dosing 70 mpk
Stop dosing 30 and 10 mpk

FIG. 12




Tumor volume start of treatment
TGI
CR/PR n=10
300 mm3
>94%
1/7
500 mm3
>86%
2/8
1000 mm3
>80%
1/8
1000mm3
500mm3
300mm3
Stop dosing
Mean Tumor Volume (mm3 ± SE)
Days Post Staging
0
100
200
300
400
500
600
700
800
900
1000
0
10
20
30
40
50
60
70
80

FIG. 13


4. Ex. 166 30MPK
>96% TGI, (1CR, 9PR)
5. Ex. 166 30MPK, 7ON, 7 OFF
>94% TGI (6 PR)
6. Ex. 166 30MPK, QOD
>94% TGI (9 PR)
Start dosing
Mean tumor volume (mm3)(± SE)
Days post-staging
0
50
100
150
200
250
300
0
5
10
15
20
25
30